Why the study?
Does reperfusion therapy improve in-hospital and 6-month mortality in diabetic patients with ST-segment elevation myocardial infarction compared to conservative treatment?
Does reperfusion therapy improve in-hospital and 6-month mortality in diabetic patients with ST-segment elevation myocardial infarction compared to conservative treatment?
Reperfusion therapy (invasive or fibrinolysis) in diabetic patients with STEMI significantly improves prognosis, reducing mortality to levels comparable to nondiabetic patients and overcoming the high mortality associated with conservative management.
Answers are grounded in this paper and cite their sources.
Reperfusion may equalize 6-month mortality in diabetic versus nondiabetic STEMI; hypothesis-generating but leaves open need for randomized confirmation.
BACKGROUND: Diabetic patients have a 6-fold increased mortality in acute coronary syndromes. HYPOTHESIS: Different therapeutic strategies in diabetics with acute coronary syndromes have an impact on in-hospital and long-term prognosis. METHODS: A total of 889 consecutive patients with ST-segment elevation myocardial infarction were included and followed-up for at least 6 months. The study population consisted of 168 (18.9%) diabetic patients and 721 nondiabetics. RESULTS: Invasive therapy and fibrinolysis were less frequently used in diabetic patients (38.7% versus 50.2%; p = 0.0071 and 8.3% versus 15%; p = 0.024, respectively). In-hospital mortality in diabetic individuals was almost twice as high as in nondiabetic subjects (20.2% versus 11.1%; p < 0.0014). In-hospital mortality was slightly higher in diabetic patients undergoing primary percutaneous transluminal coronary angioplasty (PTCA; 8.3% versus 4.8%; p = 0.35), but lower in those treated with fibrinolysis (7.7% versus 16%; p = 0.7) compared with the rest of the patients. At 6-mo follow-up mortality was significantly higher in diabetic subjects as compared with nondiabetic subjects (28.0% versus 15.1%; p < 0.0001). The highest number of deaths was found in individuals receiving conservative treatment with diabetic subjects significantly outnumbering nondiabetic individuals (40.1% versus 27.9%; p = 0.028 at 6 mo). Both in-hospital and 6-mo mortality were similar in diabetics and nondiabetics receiving reperfusion therapy (7.1% versus 8.2%; p < 0.68 and 9.3% versus 15.3%; p < 0.098, respectively). CONCLUSION: Reperfusion therapy, both fibrinolysis and the invasive approach, reduced in-hospital mortality from that observed in nondiabetic individuals.
No takes yet. Share an insight, caveat, or question.
Janion et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: